Leptin Silencing Attenuates Lipid Accumulation through Sterol Regulatory Element-Binding Protein 1 Inhibition in Nasopharyngeal Carcinoma.
NPC
SREBP1
leptin
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
20 May 2022
20 May 2022
Historique:
received:
24
04
2022
revised:
18
05
2022
accepted:
19
05
2022
entrez:
28
5
2022
pubmed:
29
5
2022
medline:
1
6
2022
Statut:
epublish
Résumé
Leptin is a crucial regulator of metabolism and energy homeostasis in mammals. Many studies have investigated the impacts of leptin on human cancers, such as proliferation and metastasis. However, the mechanisms underlying leptin-mediated regulation of lipid metabolism in nasopharyngeal carcinoma (NPC) remain incompletely understood. In the current study, leptin downregulation ameliorated lipid accumulation, triglyceride, and cholesterol levels. Mechanistically, diminished leptin by siRNA not only inhibited sterol regulatory element-binding protein 1 (SREBP1), a master regulator of lipid metabolism, at the mRNA and protein levels, but also reduced SREBP1 downstream target expressions, such as fatty acid synthase (FASN) and stearoyl-CoA desaturase-1 (SCD1), in NPC cells. In addition, leptin expression could modulate the promoter activity of SREBP1. We also found that pharmacological inhibition of poly-ADP ribose polymerase-γ (PPAR-γ) resulted in increased SREBP1 expression in leptin-depleted NPC cells. Functionally, SREBP1 overexpression overcame the effects of leptin-silencing attenuated triglyceride level, cholesterol level and cell survival in NPC cells. Taken together, our results demonstrate that leptin is an important regulator of lipid metabolism in NPC cells and might could be a potential therapeutic target for treatment of NPC patients.
Identifiants
pubmed: 35628510
pii: ijms23105700
doi: 10.3390/ijms23105700
pmc: PMC9146162
pii:
doi:
Substances chimiques
Leptin
0
SREBF1 protein, human
0
Sterol Regulatory Element Binding Protein 1
0
Triglycerides
0
Cholesterol
97C5T2UQ7J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Kaohsiung Chang Gung Memorial Hospital
ID : CMRPG8H1011-3
Organisme : Chung Shan Medical University
ID : RD11005
Références
Cell Cycle. 2012 Jun 15;11(12):2348-58
pubmed: 22672904
Cancer Commun (Lond). 2018 May 21;38(1):27
pubmed: 29784041
Radiat Oncol. 2019 Jan 17;14(1):9
pubmed: 30654815
Theranostics. 2020 May 30;10(16):7053-7069
pubmed: 32641978
Oncol Rep. 2017 Oct;38(4):2105-2115
pubmed: 28765876
J Cancer. 2019 Jun 2;10(12):2706-2719
pubmed: 31258779
Sci Adv. 2021 Feb 10;7(7):
pubmed: 33568479
Oncotarget. 2015 Mar 30;6(9):7166-81
pubmed: 25704884
J Surg Res. 2003 Jul;113(1):50-5
pubmed: 12943810
Tumour Biol. 2015 Jun;36(6):4133-41
pubmed: 25589463
J Pathol. 2018 Oct;246(2):180-190
pubmed: 29968360
Nature. 2017 Jan 5;541(7635):41-45
pubmed: 27974793
Cancer Res. 2020 Dec 1;80(23):5174-5188
pubmed: 33067266
Cell Death Differ. 2019 May;26(5):843-859
pubmed: 29988076
Front Oncol. 2022 Jan 03;11:780410
pubmed: 35047398
Int J Mol Sci. 2021 Mar 11;22(6):
pubmed: 33799880
Antioxid Redox Signal. 2018 Feb 10;28(5):339-357
pubmed: 28665143
Am J Physiol Endocrinol Metab. 2017 Jan 1;312(1):E11-E18
pubmed: 27827807
Ann Surg Oncol. 2009 Feb;16(2):297-303
pubmed: 19050975
Front Oncol. 2020 Aug 21;10:1510
pubmed: 32974183
Neural Plast. 2016;2016:2754078
pubmed: 27547453
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Lancet. 2019 Jul 6;394(10192):64-80
pubmed: 31178151
J Cell Biochem. 2015 Sep;116(9):2039-48
pubmed: 25752935
Cancer Lett. 2022 Jan 28;525:46-54
pubmed: 34610416
Intern Med Rev (Wash D C). 2017 May;3(5):
pubmed: 29034362
Endocrinology. 2009 May;150(5):2169-74
pubmed: 19147673
Oncogene. 2015 Oct 1;34(40):5128-40
pubmed: 25619842
Mol Oncol. 2020 Dec;14(12):3234-3252
pubmed: 33064888
Acta Biochim Biophys Sin (Shanghai). 2019 Jul 10;51(7):707-714
pubmed: 31187140
Oncotarget. 2017 Nov 25;8(65):109417-109435
pubmed: 29312618
PPAR Res. 2019 Aug 01;2019:8679271
pubmed: 31467515
Philos Trans R Soc Lond B Biol Sci. 2017 Oct 19;372(1732):
pubmed: 28893937
Cancer Res. 2007 Mar 15;67(6):2497-507
pubmed: 17363567
Biochem Biophys Res Commun. 2017 Jan 22;482(4):1246-1251
pubmed: 27939887
J Exp Clin Cancer Res. 2018 Jun 15;37(1):118
pubmed: 29907133
Theranostics. 2018 Mar 22;8(9):2329-2347
pubmed: 29721083
Expert Rev Mol Med. 2007 May 04;9(12):1-24
pubmed: 17477889
Endocr Rev. 2021 Jan 28;42(1):1-28
pubmed: 33150398
Mol Cell Biol. 2017 Oct 27;37(22):
pubmed: 28827316
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
PLoS One. 2012;7(3):e33823
pubmed: 22457791
Prostaglandins Leukot Essent Fatty Acids. 2010 Apr-Jun;82(4-6):243-50
pubmed: 20206487
J Exp Med. 2021 Jan 4;218(1):
pubmed: 33601415
Mol Nutr Food Res. 2018 May;62(10):e1700701
pubmed: 29508519
Biomolecules. 2021 Jun 20;11(6):
pubmed: 34202969
Int J Biochem Cell Biol. 2016 Mar;72:18-26
pubmed: 26772821
Ann Biol Clin (Paris). 2020 Jun 1;78(3):231-242
pubmed: 32540812
Cell Cycle. 2015;14(16):2667-76
pubmed: 26017929
Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4637-41
pubmed: 9114043
Oncogene. 2013 Oct 17;32(42):5111-22
pubmed: 23208501
Cancer Metab. 2013 Jan 23;1(1):3
pubmed: 24280005
Hepatology. 2022 Jan 25;:
pubmed: 35076948
Cancer Causes Control. 2000 May;11(5):383-8
pubmed: 10877331